Our findings suggested that niraparib increased the expression of KDM5A in cervical cancer cells and promoted its binding to the Pten promoter region, resulting in reduced transcription and translation of Pten. The decrease of PTEN expression activated PI3K-AKT-S6K1 pathway and increased the expression of PD-L1, which was consistent with the conclusion previously reported that the deletion of PTEN causes an increase in PD-L1 expression in tumor cells (Song et al. 2013). The gene discussed is AKT1; the disease is cervical carcinoma.